If that was the recent constant seller finally getting out then that's great.May be a one off though.we will see if it gets back in dollar country and no one appears....
Printable View
He's winging his way to Auckland for the weekend...
The CEO of Predictive suggested at the time they lost CMS coverage that it would take 18-24 months to complete a clinical utility study and have it reviewed and published etc. But instead they walked away from the $77m invested and shut shop. 90 employees losing jobs..
They had previously conducted a study of 733 patients and came up with what seemed like very good results. And these were peer reviewed and published . Lab approved, all go. $1.0m sales 2011, $4.2m 2012 and on track to reach $14.2m 2013. 10% of US Urologists had ordered the tests which cost $380.
All very queer, and agree - not to be disregarded...
Bloody stop loss saw me lose nearly a quarter of my PEB holding at 95 cents yesterday. I'm a newbie investor and still learning the ropes. After getting burned on Diligent (still holding at a big loss), I decided stop losses are important, even for long term investors. In hindsight, I should have set it a bit lower though. Oh well, live and learn. I'll wait until the preliminary full year report is out before deciding whether to reinvest those funds in PEB. Are these reports usually released after the market is closed, or do I need to remain glued to my screen next Friday?
I am but an investor as against the clinically knowledgeable people.Perhaps Hancocks may comment but from my investor DYOR position I find the statement quite concerning.We are still in that period of uncertainty and unrest despite relative calm today in the market.
Darling explains the three independent, but related, pieces of IP associated with the Cxbladder technology. That ‘juice’ is number one. The second is an algorithm that combines the information from the gene expression patterns into a single digit output defining the probability that the patient has cancer. The third is the patents that define the five genes that “create the relationship between the disease and the genes.
“On the subject of competitors, he says there were US ventures starting out the same time as them. However, these “gene jockeys”, as he calls them, were using very different, less robust, gene discovery processes. By exercising tighter controls and consistent processes, Pacific Edge simply stole the edge on their American counterparts. “We were out of the blocks early and able to get a good position in the market by filing these genes and their relationship to the cancers as part of our IP,”
http://exportermagazine.co.nz/comment/reply/2595